Allogeneic T Cell Therapies Market Report, 2024-2028 & 2033 - Valued at $1.16 Billion in 2024, the Industry is Forecast to Generate Revenues of $1.69 Billion by 2028
12 déc. 2024 05h38 HE
|
Research and Markets
Dublin, Dec. 12, 2024 (GLOBE NEWSWIRE) -- The "Allogeneic T Cell Therapies Market, 2024-2028 & 2033" report has been added to ResearchAndMarkets.com's offering. The allogeneic T cell...
CAR T-cell Therapy Strategic Business Research Report 2024: Global Market to Reach $10.8 Billion by 2030 - Expanding Clinical Applications Beyond Blood Cancers Expands Opportunities
02 déc. 2024 06h31 HE
|
Research and Markets
Dublin, Dec. 02, 2024 (GLOBE NEWSWIRE) -- The "CAR T-cell Therapy - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for CAR T-cell...
Gene Editing Market Forecast Report 2024, with Profiles of Merck, GenScript, Revvity, Lonza, Precision BioSciences, Cellectis, AMSBIO, Synthego, Takara Bio, Bio-Techne, Reprocell and More
29 nov. 2024 04h43 HE
|
Research and Markets
Dublin, Nov. 29, 2024 (GLOBE NEWSWIRE) -- The "Gene Editing Market by Product (Kits, Reagents, Libraries, Software), Services (GRNA Synthesis & Vector Construction), Technique, Technology...
Cell and Gene Therapy Tools and Reagents Market Report 2024 - Driving Medical Advances: Cell and Gene Therapy Tools Market to Hit $16.7 Billion by 2029
29 nov. 2024 04h24 HE
|
Research and Markets
Dublin, Nov. 29, 2024 (GLOBE NEWSWIRE) -- The "Cell and Gene Therapy Tools and Reagents Market" report has been added to ResearchAndMarkets.com's offering.The Cell and Gene Therapy Tools and...
Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion
15 nov. 2024 11h02 HE
|
Barinthus Biotherapeutics
Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B
15 nov. 2024 11h01 HE
|
Barinthus Biotherapeutics
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with
Cell and Gene Therapy CRO Market Research Trends and Global Forecasts, 2024-2035: Over 105 CROs Drive Innovation, with 80% Ensuring Comprehensive Support from R&D to Clinical Trials
04 nov. 2024 05h40 HE
|
Research and Markets
Dublin, Nov. 04, 2024 (GLOBE NEWSWIRE) -- The "Cell and Gene Therapy CRO Market: Industry Trends and Global Forecasts, Till 2035 - Distribution by Type of Cell Therapy, Type of Genetic Modification,...
Barinthus Bio Announces Late Breaking Presentation at AASLD 2024 – The Liver Meeting® and Attendance at November Conferences
31 oct. 2024 08h00 HE
|
Barinthus Biotherapeutics
Barinthus Bio Announces Late Breaking Presentation at AASLD 2024 – The Liver Meeting® and Attendance at November Conferences
Tevogen Bio Provides Additional Guidance on Introduction of T Cell Therapy for Oncology and Specialty Care Therapeutic Areas
25 oct. 2024 17h34 HE
|
Tevogen Bio Inc
WARREN, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf,...
Spain CAR-T Cell Therapy Market Forecast to 2029, Featuring Strategic Profiles of Gilead Sciences, Novartis Int'l, Bristol Myers Squibb, AbbVie, AMGEN, Pfizer, Merck & Co, Johnson & Johnson
23 oct. 2024 12h03 HE
|
Research and Markets
Dublin, Oct. 23, 2024 (GLOBE NEWSWIRE) -- The "Spain CAR-T Cell Therapy Market, By Region, Competition, Forecast & Opportunities, 2019-2029F" report has been added to ResearchAndMarkets.com's...